HSP90AA1 and systemic sclerosis: It has been found, for instance, that increased expression of Hsp90 in the skin of patients with SSc is critical for TGF-β signaling and that a pharmacological blockade of Hsp90 inhibited the profibrotic effects of TGF-β in cultured fibroblasts and in animal models of SSc [65].